Phase 3 N=19 Blood Pressure, Cerebral Blood Flow and Cognition in Spinal Cord Injury
Spinal Cord Injury
Primary: Systolic Blood Pressure — 116.3; 98.0 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=168 A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)
Pulmonary Arterial Hypertension · Hypertension, Pulmonary
Primary: Phase 2 Cohort: Mean Percent Change From Baseline in Pulmonary Vascular Resistance (PVR) at 12 Weeks — 4.3; -4.9; -17.6; -15.6 Percentage Change — p=0.068
Phase 3 N=761 Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
Nonsquamous Non-small Cell Lung Cancer
Primary: Part 1: Number of Participants With a Dose-limiting Toxicity (DLT) — 2 Participants
Phase 3 N=877 Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis
Multiple Sclerosis
Primary: Annualized Confirmed Relapse Rate (ARR) — 0.143; 0.184 relapses per patient-year
Phase 3 N=66 Treatment of Post-SCI Hypotension
Spinal Cord Injury · Autonomic Dysreflexia · Orthostatic Hypotension
Primary: Affected Therapy Sessions — 16.4; 10.9 percentage of sessions
Phase 3 N=98 Aggrenox To Treat Acute Covid-19
Covid19
Primary: Covid (Coronavirus Disease-19) Ordinal Scale — 2.3; 2.1 score on a scale
Phase 3 N=40 Efficacy of Eco-Friendly Toothpaste Tablets Versus Conventional Toothpaste Using PI and GI Index
Gingival Inflammation
Primary: Plaque Index Score at Baseline — 2.80; 2.78 Score on a scale
Phase 3 N=258 To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
Chronic Kidney Disease Associated Moderate to Severe Pruritus
Primary: Percentage of Responders With an Improvement of Worst Itch Numeric Rating Scale (WI NRS) Greater Than and Equal to (>=) 4 From Baseline at Week 12 — 38.5; 47.7; 32.4…
Phase 3 N=120 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
Gastric Cancer · Gastroesophageal Junction Cancer
Primary: Event-free Survival (EFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms — NA; 36.5 Months…
Phase 3 N=526 A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin
Diabetes Mellitus, Type 2
Primary: Change in Glycated Haemoglobin (HbA1c) — -0.93; -0.71 Percentage of HbA1c — p=<0.0001
Phase 3 N=285 Efficacy and Safety of VVZ-149 Injections in Patients Undergoing Laparoscopic Colectomy
Pain, Postoperative · Acute Pain
Primary: Time-weighted Sum of Pain Intensity Differences for 12 Hours Post-dose (SPID 12) — 26.83; 19.89 score on a scale*hours — p=0.0047
Phase 3 N=1,007 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
Gastric Cancer · Gastroesophageal Junction Cancer
Primary: Event-free Survival (EFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms — 44.4; 25.7 Months…
Phase 3 N=241 A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants
Acute Migraine
Primary: Treatment Safety Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 203 Participants
Phase 3 N=248 A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
ALK+ Advanced NSCLC
Primary: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 — 19.253; 19.187 months — p==0.8672
Phase 3 N=8 A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
Heart Failure
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 1 Participants